drugset / Trial / NCT00756002

Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia

NCT00756002

Phase 3 Completed 259 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of 4 mg of Ramelteon, once daily (QD), in subjects with chronic insomnia.

Timeline

Start
2007-08
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown 4 mg Oral